Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women

To prevent the global health burdens of human immunodeficiency virus [HIV] and unintended/mistimed pregnancies, we developed an intravaginal ring [IVR] that delivers tenofovir [TFV] at ~10mg/day alone or with levonorgestrel [LNG] at ~20μg/day for 90 days. We present safety, pharmacokinetics, pharmac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Thurman, Andrea Ries, Schwartz, Jill L., Brache, Vivian, Clark, Meredith R., McCormick, Timothy, Chandra, Neelima, Marzinke, Mark A., Stanczyk, Frank Z., Dezzutti, Charlene S., Hillier, Sharon L., Herold, Betsy C., Fichorova, Raina, Asin, Susana N., Rollenhagen, Christiane, Weiner, Debra, Kiser, Patrick, Doncel, Gustavo F.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6023238/
https://ncbi.nlm.nih.gov/pubmed/29953547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0199778
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados